Nonnucleoside reverse transcriptase inhibitors.

Robert Leo Murphy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Nonnucleoside transcriptase inhibitors (NNRTIs) are potent antiretroviral agents that can successfully be used in appropriate HIV/AIDS triple-therapy regimens, although resistance can develop rapidly. The two primary advantages of initiating NNRTIs therapy are that it delays the use of protease inhibitors and the NNRTIs regimen is easier to adhere to and can be given once per day. Nevirapine and delavirdine, two NNRTIs that have been approved for clinical use, are examined, and loviride, efavirenz, and HBY 097, currently under development, are discussed. The advantages, disadvantages, and pharmacologic characteristics of each drug are highlighted.

Original languageEnglish (US)
JournalAIDS clinical care
Issue number10
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Nonnucleoside reverse transcriptase inhibitors.'. Together they form a unique fingerprint.

Cite this